A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
ApexOnco Front Page
Recent articles
With a slashed valuation the newly listed biotech heads for phase 3.
Posters and mini-orals include another VEGF bispecific.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Summit and Nuvalent have scored prized plenary spots.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Inclacumab fails, and osivelotor is on hold.
Shortly after ponsegromab, visugromab is to start phase 2/3.
